Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2 : Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies
© 2023 Wiley Periodicals LLC..
Emergence of various circulating SARS-CoV-2 variants of concern (VOCs) promotes the identification of pan-sarbecovirus vaccines and broadly neutralizing antibodies (bNAbs). Here, to characterize monoclonal antibodies cross-reactive against both SARS-CoV-1 and SARS-CoV-2 and to search the criterion for bNAbs against all emerging SARS-CoV-2, we isolated several SARS-CoV-1-cross-reactive monoclonal antibodies (mAbs) from a wildtype SARS-CoV-2 convalescent donor. These antibodies showed broad binding capacity and cross-neutralizing potency against various SARS-CoV-2 VOCs, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta), but failed to efficiently neutralize Omicron variant and its sublineages. Structural analysis revealed how Omicron sublineages, but not other VOCs, efficiently evade an antibody family cross-reactive against SARS-CoV-1 through their escape mutations. Further evaluation of a series of SARS-CoV-1/2-cross-reactive bNAbs showed a negative correlation between the neutralizing activities against SARS-CoV-1 and SARS-CoV-2 Omicron variant. Together, these results suggest the necessity of using cross-neutralization against SARS-CoV-1 and SARS-CoV-2 Omicron as criteria for rational design and development of potent pan-sarbecovirus vaccines and bNAbs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of medical virology - 95(2023), 2 vom: 09. Feb., Seite e28440 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Shibo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2023 Date Revised 02.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.28440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350849226 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350849226 | ||
| 003 | DE-627 | ||
| 005 | 20231226045924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.28440 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350849226 | ||
| 035 | |a (NLM)36573441 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Shibo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2 |b Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2023 | ||
| 500 | |a Date Revised 02.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Emergence of various circulating SARS-CoV-2 variants of concern (VOCs) promotes the identification of pan-sarbecovirus vaccines and broadly neutralizing antibodies (bNAbs). Here, to characterize monoclonal antibodies cross-reactive against both SARS-CoV-1 and SARS-CoV-2 and to search the criterion for bNAbs against all emerging SARS-CoV-2, we isolated several SARS-CoV-1-cross-reactive monoclonal antibodies (mAbs) from a wildtype SARS-CoV-2 convalescent donor. These antibodies showed broad binding capacity and cross-neutralizing potency against various SARS-CoV-2 VOCs, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta), but failed to efficiently neutralize Omicron variant and its sublineages. Structural analysis revealed how Omicron sublineages, but not other VOCs, efficiently evade an antibody family cross-reactive against SARS-CoV-1 through their escape mutations. Further evaluation of a series of SARS-CoV-1/2-cross-reactive bNAbs showed a negative correlation between the neutralizing activities against SARS-CoV-1 and SARS-CoV-2 Omicron variant. Together, these results suggest the necessity of using cross-neutralization against SARS-CoV-1 and SARS-CoV-2 Omicron as criteria for rational design and development of potent pan-sarbecovirus vaccines and bNAbs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-1 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a broadly neutralizing antibody (bNAb) | |
| 650 | 4 | |a cross-reactivity | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Wu, Jianbo |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Weiyu |e verfasserin |4 aut | |
| 700 | 1 | |a He, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yunjiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yidan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Minxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Anqi |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jiaying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yuru |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Guangqi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiujing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zheen |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Christian T |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiangxi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junqing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhenguo |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Shibo |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 95(2023), 2 vom: 09. Feb., Seite e28440 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:2 |g day:09 |g month:02 |g pages:e28440 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.28440 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 2 |b 09 |c 02 |h e28440 | ||